And Then There Were Six…FDA Green Lights Hugel’s Toxin for Glabellar Lines
The Dermatology Digest
MARCH 5, 2024
Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the second half of 2024. Hugel filed its first Biologics License Application in 2021, which was rejected by the FDA in 2022. Hugel resubmitted its application in October 2022 and was denied approval again in 2023.
Let's personalize your content